SHINE Building One Construction Complete
February 13, 2018 – Janesville, WI – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that it has completed construction and taken occupancy of Building One, the first building of the SHINE medical isotope production campus.
After breaking ground in August of 2017, JP Cullen completed the 6-month construction project three weeks ahead of schedule and on budget, with zero OSHA-recordable incidents. The 11,400 sq. ft. Building One will be one of the most advanced, private, nuclear technology facilities in the world. Buildout inside the building is starting now and during summer 2018 the facility will be used to house the first integrated, full-size SHINE production system. During construction of SHINE’s main production facility, Building One will be used to train employees and develop operating history with equipment. Going forward, Building One will be a state-of-the-art technology development center.
“Building One’s name was chosen because it’s intended to be a technological genesis building,” said Greg Piefer, founder and CEO of SHINE. “It will be a laboratory in which we continue to develop new technologies to keep SHINE at the forefront of medical isotope production and nuclear innovations beyond that.”
The completion of Building One comes as the company prepares to break ground on its main production facility in Janesville, Wisconsin, after receiving its construction permit from the U.S. Nuclear Regulatory Commission in 2016. The SHINE facility will produce molybdenum-99 and other medical isotopes used to detect and treat a wide variety of diseases, including heart disease and cancer.
Molybdenum-99 (Mo-99) is a radioisotope that decays into the diagnostic imaging agent technetium‑99m (Tc-99m). Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer. SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce medical isotopes, including Mo‑99.
About SHINE Medical Technologies, Inc.
Founded in 2010, SHINE is a development-stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies, as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for molybdenum-99. In 2014, SHINE announced the execution of molybdenum-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE molybdenum-99 can act as a drop-in replacement for reactor-based moly-99. In 2016, SHINE received regulatory approval to construct its facility from the Nuclear Regulatory Commission and signed a moly-99 supply agreement with HTA Co., Ltd., the largest Chinese distributor of radiopharmaceuticals. Learn more at https://shinemed.com.